The most transparent providers
Ranked on whether the advertised price is the billed price, and whether the company tells you where the medication comes from.
Updated 2026-09-18
Disclosure: one company on this page — Coreage Rx — pays us a commission when a reader signs up through our link. It does not buy a better score, a higher ranking, or the removal of any criticism. The scoring rubric and the full disclosure are both published.
Transparency is not a vague virtue in this market — it is measurable. Does the advertised number match the billed number, and will the company tell you which pharmacy made your medication?
We score price honesty as its own criterion at 20% of the total, and pharmacy sourcing at 15%. This page lists only the providers scoring 4 or better on price honesty, which is a higher bar than most of this market clears.
Inclusion criteria
- Scores 4.0 or better on price honesty — the advertised figure broadly matches the billed one.
- Ranked on the full rubric, with sourcing disclosure contributing.
- Providers with an advertised-to-billed gap are excluded by definition.
7 of the 21 providers we track qualify. Pricing verified 2026-09-18 and re-checked periodically.
The list
| # | Provider | Per month | Per year | Score |
|---|---|---|---|---|
| 1 | Coreage Rx | $199 | $2,388 | 4.5 |
| 2 | Trimi | $125 | $1,500 | 4.6 |
| 3 | PlexusDx | $189 | $2,268 | 4.4 |
| 4 | Ozari Health | $125 | $1,500 | 4.4 |
| 5 | Fifty 410 | $133 | $1,596 | 4.2 |
| 6 | Ivím Health | $199 | $2,388 | 4 |
| 7 | Remedy Meds | $399 | $4,788 | 3.5 |
Cheapest qualifying option: Trimi at $125 a month. Our featured partner is pinned to the top of the list where it qualifies — see how we rate for who scores higher.
1. Coreage Rx — Best overall on true monthly cost
$199 a month, no membership fee. Flat-rate telehealth program for compounded GLP-1s. The medication, the clinician visits and the ongoing check-ins are quoted as one number, with no separate membership billed alongside it.
The $99 and $149 rates are annual-plan prices. If you want month-to-month, budget $149 and $199 instead, and check the refund terms before prepaying a year. Read the full Coreage Rx review.
2. Trimi — Lowest flat price with named pharmacies
$125 a month, no membership fee. Flat-rate compounded GLP-1 programme on annual plans, with medical oversight through the Arora Health clinician network and publicly named 503A compounding pharmacies.
Both headline prices are annual-plan rates. Confirm the month-to-month figure and the refund terms before prepaying twelve months. Read the full Trimi review.
3. PlexusDx — Pharmacy transparency and genetic testing
$189 a month, no membership fee. Prescription GLP-1 and peptide programmes with no membership fee, built around genetic testing, using independent clinicians and a publicly listed set of 503A pharmacies.
The advertised "from $129" is the programme floor. Budget $189/month for the compounded injection tier. Read the full PlexusDx review.
4. Ozari Health — Lowest advertised semaglutide price
$125 a month, no membership fee. Flat-rate compounded GLP-1 telehealth service operating in all 50 states, with physician review through the Arora Health network and a dedicated health concierge.
Confirm whether $86 is a month-to-month rate or requires a longer commitment, and ask which pharmacy compounds it. Read the full Ozari Health review.
Frequently asked
What counts as a transparency failure?
Advertising a medication price while billing a separate membership; quoting a sublingual or microdose price for what people read as the weekly injection; and advertising one ongoing rate while the checkout charges another.
Does transparency mean cheaper?
Often, but not always. A transparent provider can be expensive — it simply tells you so up front, which is what you want.
What the price does not tell you
Compounded preparations are not FDA-approved. Two approved oral GLP-1s now start around $149 a month, and from 1 July 2026 eligible Medicare beneficiaries can access certain GLP-1s for $50 a month — both of which beat a large part of this market. See the approved pills and the Medicare programme.
In SURMOUNT-1, adults with obesity lost an average of 19.5% of body weight on 10 mg and 20.9% on 15 mg over 72 weeks. That figure comes from a controlled trial of the active ingredient, not from any particular seller's product.
Read next
- Who names their pharmacy
The hardest fact to get out of this market, and the one the FDA’s enforcement actually turns on. Here is who publishes it.